Today, Omni Hospitals Owned By Conglomerate Eddy Kusnadi Sariaatmadja Confirms The Acquisition Of Kedoya Hospital Manager For Rp719 Billion

JAKARTA - The manager of Omni Hospitals, PT Sarana meditama metropolitan Tbk (SAME) has confirmed that it will add 47.51 percent of its shares in the new hospital issuer, PT Kedoya Adyaraya Tbk (RSGK). In the future, SAME will be the largest shareholder and controller of the company.

In the SAME prospectus, quoted Tuesday, October 26, the issuer of the Emtek Group hospital owned by conglomerate Eddy Kusnadi Sariaatmadja has a plan to buy back up to 441,734,500 RSGK shares or 441.73 million shares or representing a maximum of 47.51 percent of the shares of the issued and fully paid up capital of RSGK.

In detail, 45 percent of the shares will be purchased based on the Sale and Purchase Binding Agreement (PPJB) with PT Bestama Medikacenter Investama (BMI) and PT Medikatama Sejahtera (MS) at a price of Rp1,720 per share.

"Therefore, the total share price is Rp719,564,580,000 or Rp719.56 billion and 2.51 percent of the shares will be purchased from the public on the IDX regular market with the purchase price following the prevailing market price at the time the purchase was made," explained SAME management.

Through the purchase of RSGK shares, SAME will own a maximum of 613,585,500 or 613.58 million shares or a maximum of 66 percent of the issued and fully paid capital in RSGK and a takeover occurs in RSGK.

This is because previously SAME already held 18.49 percent of RSGK shares from the transaction results of Rp287,824,800,000 or Rp287.82 billion, consisting of 171,851,000 or 171.85 million shares of RSGK.

The RSGK share ownership was obtained by the company based on the RSGK initial public offering of 0.49 percent purchased on September 6, 2021 and the Sale and Purchase Binding Agreement between the company and PT United Gramedo (UG) on September 8, 2021 at 18 percent.

Payment for the purchase of shares will be made in cash by SAME from the funds received by the company based on the results of the company's additional capital by providing Pre-emptive Rights through a Limited Public Offering II on July 2, 2021.

"As for considering that the amount of funds is not sufficient to purchase the majority of RSGK shares, the company will use funds derived from the company's current year profit, which is based on the company's internal calculations, until September 30, 2021 the company has sufficient EBITDA to carry out transactions," said SAME management.